Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.

Luis Querol*, Ricard Rojas-Garcia, Carlos Casasnovas, Maria Jose Sedano, Jose Luis Muñoz-Blanco, Maria Antonia Alberti, Carmen Paradas, Teresa Sevilla, Julio Pardo, Jose Luis Capablo, Rafael Sivera, Antonio Guerrero, Eduardo Gutierrez-Rivas, Isabel Illa

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

The objective of this retrospective study was to describe the short- and long-term patterns of IVIg use, safety, and response to treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Response to therapy was defined as an improvement of ≥ 1 point on the modified Rankin score at short- and mid-term visits. Patient status at long term was classified as remission, stability, or non-responder. Eighty-six patients were included; 60.5% responded at short term and 54.6% at mid-term. At long term, 25.6% of patients were in remission, 65.1% were stable, and 9.3% were non-responders. The only variable associated with remission was a better response during the first 6 months of follow-up. A significant percentage of patients did not require any additional drugs in the long term. This suggests that treatment effect or disease outcome may be stable over time, and treatment regimens should therefore be individualized to avoid overtreatment.

Original languageEnglish
Pages (from-to)870-876
Number of pages7
JournalMuscle & Nerve
Volume48
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Dive into the research topics of 'Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.'. Together they form a unique fingerprint.

Cite this